Laura Koivusalo

StemSight is a pre-clinical stage company developing allogeneic cell-based therapies from iPS cells to treat corneal diseases. Our technology platform using proprietary differentiation methods and biomaterial carriers have spun out two different products. We showcase our technology in the rare disease limbal stem cell deficiency, a high unmet need.